

causing their proprietary capital ratios to be less than 30 percent. The extent to which the oil pipeline company has amounts loaned or money advanced to its parent, subsidiary, or affiliated companies through its cash management program(s) should also be reported, along with plans, if any, to regain at

least a 30 percent proprietary capital ratio.

(d) In the event that the proprietary capital ratio subsequently meets or exceeds 30 percent, oil pipeline companies subject to the provisions of the Commission's Uniform System of Accounts prescribed in part 352 and

§ 357.2 of this title that participate in cash management programs must notify the Commission within 45 days after the end of each calendar quarter.

Note: This appendix will not be published in the *Code of Federal Regulations*.

Appendix

LIST OF COMMENTERS ON THE INTERIM RULE

Respondent	Abbreviation
Alliance Pipeline, LP	Alliance.
American Public Gas Association	APGA.
Association of Oil Pipe Lines	AOPL.
Chevron Pipe Line Company	CPL.
Cinergy Corporation	Cinergy.
Duke Energy Corporation	Duke Energy.
Edison Electric Institute	EEL.
El Paso Corporation's Pipeline Group	El Paso.
Exelon Corporation	Exelon.
First Energy Corporation	FirstEnergy.
Graham County Electric Cooperative, Inc	GCEC.
Gulf South Pipeline Company, LP	Gulf South.
Gulfterra Energy Partners, LP	Gulfterra.
Interstate Natural Gas Association of America	INGAA.
National Rural Electric Cooperative Association	NRECA.
National Grid USA	National Grid.
National Association of Regulatory Utility Commissioners	NARUC (late comment).
NiSource Inc	NiSource.
OKTex Pipe Line Co	OKTex.
PacifiCorp	PacifiCorp.
The PSEG Companies.	
Shell Pipeline Company LP	Shell.
Sierra Southwest Cooperative Services, Inc	SSW.
Southern California Edison Company	Edison.
Tucson Electric Power Company	Tucson.
Williams Pipe Line Company, LLP	WPL.

[FR Doc. 03-27410 Filed 10-30-03; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510 and 522

Implantation or Injectable Dosage Form New Animal Drugs; Sometribove Zinc Suspension

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendment.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Monsanto Co. The supplemental NADA provides for revised wording of the indication and precautionary labeling for sometribove zinc suspension used to

increase the production of marketable milk in healthy lactating dairy cows. The regulations are also being amended to reflect a different drug labeler code (DLC) for Monsanto Co.

DATES: This rule is effective October 31, 2003.

FOR FURTHER INFORMATION CONTACT:

Suzanne J. Sechen, Center for Veterinary Medicine (HFV 126), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0221, e-mail: ssechen@cvm.fda.gov.

SUPPLEMENTARY INFORMATION: Monsanto Co., 800 North Lindbergh Blvd., St. Louis, MO 63167, filed a supplement to NADA 140-872 that provides for the use of POSILAC (sometribove zinc suspension) to increase the production of marketable milk in healthy lactating dairy cows. The supplemental NADA provides for revised precautionary labeling. The application is approved as of September 11, 2003, and the regulations are amended in 21 CFR 522.2112 to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In addition, Monsanto Co. has changed their DLC. At this time, 21 CFR 510.600(c) is being amended to reflect this DLC change.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the